23 Mar 2026

CRC Research Update — March 23, 2026

Creator: The CRC Digest
Published: 2026-03-23T11:35:31Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Primary tumor management varies in MSI-H metastatic CRC treated with immunotherapy
A single-center cohort study of 210 MSI-H/dMMR metastatic colorectal cancer patients treated with immune checkpoint inhibitors found that 21% had specific primary tumor outcomes, though optimal management strategies remain unclear. (ESMO Gastrointest Oncol)
Language-specific reminder calls may improve CRC screening in immigrant populations
A randomized controlled trial in Norway tested whether phone reminders in immigrants' native language combined with written reminders increased colorectal cancer screening participation compared to Norwegian-language letters alone. (Lancet Reg Health Eur)
Liquid biopsy advances for early detection of GI cancers
A review highlights emerging liquid biopsy technologies for minimally invasive detection of gastrointestinal cancers, addressing the critical need for earlier diagnosis when most patients are currently diagnosed at advanced stages. (Clin Transl Med)
Gut microbiome metabolite may reduce cetuximab effectiveness
Researchers found that butyrate, a metabolite produced by gut bacteria and present in circulation, can reduce the effectiveness of cetuximab in metastatic colorectal cancer through EGFR and AMPK-Wip1 signaling pathways, suggesting resistance mechanisms beyond genetic mutations. (Drug Des Devel Ther)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Very early-onset CRC may warrant distinct classification
A population-based cohort study suggests very early-onset colorectal cancer patients show differences in tumor biology, metastatic patterns, and survival that may justify creating a separate sub-category. (Clinical Colorectal Cancer)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

BRAF mutations shape tumor immune landscape
A review examines how BRAF mutations influence the tumor immune microenvironment and immunotherapy responses in colorectal cancer, thyroid cancer, and melanoma. (Am J Cancer Res)

⚥ Sex & Gender in CRC

Research on sex-specific differences in treatment, outcomes, and screening

Estrogen receptor may drive gender differences in early-onset CRC
Research suggests estrogen receptors may play an important role in explaining gender-based differences observed in early-onset colorectal cancer. (Clinical Colorectal Cancer)

Research continues to reveal the complexity of colorectal cancer biology and the importance of personalized approaches to screening and treatment.

CRC Research Update

Subscribe to The CRC Digest